BRISTOL-MYERS SQUIBB COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.12 USD | +2.17% |
|
-0.28% | -19.85% |
| May. 30 | Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma | MT |
| May. 30 | Bristol Myers: FDA approval for Breyanzi | CF |
Financials (USD)
| Sales 2024 * | 46.09B | Sales 2025 * | 46.06B | Capitalization | 83.29B |
|---|---|---|---|---|---|
| Net income 2024 * | -5.41B | Net income 2025 * | 10.22B | EV / Sales 2024 * | 2.65 x |
| Net Debt 2024 * | 39.03B | Net Debt 2025 * | 31.68B | EV / Sales 2025 * | 2.5 x |
| P/E ratio 2024 * |
-15.6
x | P/E ratio 2025 * |
7.77
x | Employees | 34,100 |
| Yield 2024 * |
5.86% | Yield 2025 * |
6.15% | Free-Float | 69.27% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bristol-Myers Squibb Company
More recommendations
More press releases
More news
| 1 day | +2.17% | ||
| 1 week | -0.28% | ||
| Current month | +0.09% | ||
| 1 month | -6.41% | ||
| 3 months | -18.97% | ||
| 6 months | -16.72% | ||
| Current year | -19.85% |
1 week
39.91
41.33
1 month
39.9145.72
Current year
39.9155.04
1 year
39.9166.46
3 years
39.9181.44
5 years
39.9181.44
10 years
39.9181.44
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 15-01-31 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 16-03-31 |
Derica Rice
BRD | Director/Board Member | 59 | 20-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 12.97% | 254 M€ | +13.69% | - | |
| 4.99% | 2 M€ | -.--% | ||
| 4.01% | 17 M€ | +6.09% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 41.09 | +2.09% | 29,395,143 |
| 24-05-30 | 40.25 | -.--% | 16,114,018 |
| 24-05-29 | 40.25 | -0.59% | 16,492,496 |
| 24-05-28 | 40.49 | -1.82% | 14,674,452 |
| 24-05-24 | 41.24 | -0.72% | 17,425,597 |
Delayed Quote Nyse, May 31, 2024 at 04:00 pm EDT
More quotes
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.09
USD
Average target price
53.19
USD
Spread / Average Target
+29.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.85% | 81.59B | |
| +40.73% | 734B | |
| +32.83% | 591B | |
| -6.30% | 350B | |
| +15.15% | 315B | |
| +4.05% | 276B | |
| +15.00% | 238B | |
| +9.78% | 206B | |
| -5.52% | 204B | |
| +6.17% | 161B |
- Stock Market
- Equities
- BMY Stock
